MENU
+Compare
TRVI
Stock ticker: NASDAQ
AS OF
Oct 24 closing price
Price
$10.51
Change
-$0.14 (-1.31%)
Capitalization
1.28B

TRVI Trevi Therapeutics Forecast, Technical & Fundamental Analysis

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more

TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for TRVI with price predictions
Oct 24, 2025

TRVI's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for TRVI moved out of overbought territory on October 23, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for TRVI turned negative on October 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TRVI broke above its upper Bollinger Band on October 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 26, 2025. You may want to consider a long position or call options on TRVI as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 150 cases where TRVI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.447) is normal, around the industry mean (24.402). P/E Ratio (0.000) is within average values for comparable stocks, (54.668). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.161). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (355.249).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

TRVI is expected to report earnings to rise 9.22% to -9 cents per share on November 05

Trevi Therapeutics TRVI Stock Earnings Reports
Q3'25
Est.
$-0.10
Q2'25
Beat
by $0.01
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.01
Q3'24
Missed
by $0.01
The last earnings report on August 07 showed earnings per share of -9 cents, beating the estimate of -10 cents. With 1.11M shares outstanding, the current market capitalization sits at 1.28B.
A.I. Advisor
published General Information

General Information

a developer and manufacturer of neurological products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
195 Church Street
Phone
+1 203 304-2499
Employees
25
Web
https://www.trevitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIDSX2.91N/A
N/A
Midas Discovery
EAFVX21.07N/A
N/A
Eaton Vance Focused Value Opps A
GPTUX14.07N/A
N/A
GuidePath® Tactical Allocation Svc
PNSIX20.97N/A
N/A
T. Rowe Price New Asia I
JGAQX38.67N/A
N/A
JPMorgan Value Advantage R2

TRVI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with BIESF. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-1.31%
BIESF - TRVI
43%
Loosely correlated
N/A
PTGX - TRVI
36%
Loosely correlated
+1.18%
QURE - TRVI
30%
Poorly correlated
+2.83%
XENE - TRVI
29%
Poorly correlated
-1.07%
GOSS - TRVI
28%
Poorly correlated
+18.66%
More